国家医保局发布《国家基本医疗保险、工伤保险和生育保险药品目录(2025年版)》,PD-1/CTLA-4双特异性抗体卡度尼利单抗(商品名:开坦尼®)的胃癌一线及宫颈癌一线治疗适应症被纳入医保,至此其3项适应症已全部纳入国家医保药品目录。北京大学肿瘤医院沈琳教授称,卡度尼利联合方案相比常用免疫治疗方案优势显著,既为PD-L1高表达胃癌患者一线治疗提供更优选择,又让PD-L1低表达/阴性人群有了高效...
Source Link国家医保局发布《国家基本医疗保险、工伤保险和生育保险药品目录(2025年版)》,PD-1/CTLA-4双特异性抗体卡度尼利单抗(商品名:开坦尼®)的胃癌一线及宫颈癌一线治疗适应症被纳入医保,至此其3项适应症已全部纳入国家医保药品目录。北京大学肿瘤医院沈琳教授称,卡度尼利联合方案相比常用免疫治疗方案优势显著,既为PD-L1高表达胃癌患者一线治疗提供更优选择,又让PD-L1低表达/阴性人群有了高效...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.